{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:38:07Z","timestamp":1787585887533,"version":"build-2736575974"},"reference-count":34,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>South Korean MPN patients had a significantly higher risk of developing second primary solid tumors than that of the general population. Patients with SMF had an overall survival comparable to those with PMF with less risk of developing SAML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000655","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:38:32Z","timestamp":1574681912000},"page":"3700-3708","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-397X","authenticated-orcid":false,"given":"Junshik","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-1932","authenticated-orcid":false,"given":"Sang Mee","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4837-164X","authenticated-orcid":false,"given":"Hyoung Soo","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam National University College of Medicine, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"1","key":"2019112616083637100_B1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"2019112616083637100_B2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2019112616083637100_B3","first-page":"679","article-title":"Recent advances in the diagnosis and management of primary myelofibrosis","volume":"33","author":"Takenaka","year":"2018","journal-title":"Korean J Intern Med (Korean Assoc Intern Med)"},{"issue":"5","key":"2019112616083637100_B4","first-page":"1197","article-title":"A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database","volume":"57","author":"Brunner","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019112616083637100_B5","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"2019112616083637100_B6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"2019112616083637100_B7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019112616083637100_B8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019112616083637100_B9","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3346\/jkms.2016.31.10.1579","article-title":"Incidence, survival and prevalence statistics of classical myeloproliferative neoplasm in Korea","volume":"31","author":"Lim","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"3","key":"2019112616083637100_B10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00277-016-2902-9","article-title":"Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013","volume":"96","author":"Byun","year":"2017","journal-title":"Ann Hematol"},{"issue":"16","key":"2019112616083637100_B11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019112616083637100_B12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2008.01163.x","article-title":"AML transformation in 56 patients with Ph- MPD in two well defined populations","volume":"82","author":"Abdulkarim","year":"2009","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019112616083637100_B13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"issue":"11","key":"2019112616083637100_B14","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"22","key":"2019112616083637100_B15","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","article-title":"Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia","volume":"165","author":"Chim","year":"2005","journal-title":"Arch Intern Med"},{"issue":"4","key":"2019112616083637100_B16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2010.5","article-title":"Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients","volume":"24","author":"Girodon","year":"2010","journal-title":"Leukemia"},{"issue":"23","key":"2019112616083637100_B17","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 11","key":"2019112616083637100_B18","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11+<2575::AID-CNCR15>3.0.CO;2-F","article-title":"Ethnic differences in cancer risk resulting from genetic variation","volume":"86","author":"Neuhausen","year":"1999","journal-title":"Cancer"},{"issue":"25","key":"2019112616083637100_B19","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019112616083637100_B20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428194.2015.1071492","article-title":"Risk of second primary malignancies and survival of adult patients with polycythemia vera: a United States population-based retrospective study","volume":"57","author":"Khanal","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019112616083637100_B21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","article-title":"The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Abdulkarim","year":"2011","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019112616083637100_B22","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2019112616083637100_B23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","article-title":"Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome","volume":"92","author":"Yogarajah","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"2019112616083637100_B24","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019112616083637100_B25","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"2019112616083637100_B26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"issue":"9","key":"2019112616083637100_B27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019112616083637100_B28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-018-0453-y","article-title":"Post-ET and post-PV myelofibrosis: updates on a distinct prognosis from primary myelofibrosis","volume":"13","author":"Passamonti","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2019112616083637100_B29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2019112616083637100_B30","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3109\/10428194.2014.963082","article-title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","volume":"56","author":"Chen","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019112616083637100_B31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-014-2183-0","article-title":"Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge","volume":"94","author":"Palandri","year":"2015","journal-title":"Ann Hematol"},{"issue":"3","key":"2019112616083637100_B32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"2019112616083637100_B33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ejh.12788","article-title":"Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway","volume":"98","author":"Roaldsnes","year":"2017","journal-title":"Eur J Haematol"},{"issue":"6","key":"2019112616083637100_B34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3700\/1543944\/advancesadv2019000655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3700\/1543944\/advancesadv2019000655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T16:30:00Z","timestamp":1574785800000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/22\/3700\/428870\/Risk-of-disease-transformation-and-second-primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":34,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000655","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]}}}